Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29351558 | 0.85 | CSNK2A1 (0.43) | CSNK2A1CYP1A2GSK3B | |
| SCHEMBL307261 | 0.85 | CSNK2A1 (0.43) | CSNK2A1CYP1A2GSK3B | |
| SCHEMBL5175862 | 0.83 | CSNK2A1 (0.42) | CSNK2A1CYP1A2GSK3B | |
| Phosphoric Acid SCHEMBL5423551 | 0.76 | CSNK2A1 (0.39) | CSNK2A1CYP1A2GSK3B | |
| SCHEMBL6930060 | 0.76 | CSNK2A1 (0.46) | CSNK2A1CYP1A2GSK3B | |
| SCHEMBL3144514 | 0.76 | GPR84 (0.46) | CSNK2A1CYP1A2GSK3B | |
| SCHEMBL28020005 | 0.76 | F7 (0.47) | — | |
| SCHEMBL3144513 | 0.76 | GPR84 (0.46) | GSK3B | |
| SCHEMBL30712037 | 0.74 | PRKAB2 (0.37) | CSNK2A1 | |
| SCHEMBL6930062 | 0.73 | SLC22A6 (0.51) | CSNK2A1CYP1A2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 209 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9090929-B2 | Medium for detecting and differentiating vancomycin-resistant enterococci | OXOID LIMITED (GB) | 2015-07-28 | — | — | US | claimed |
| EP-2186906-B1 | Medium for detecting and differentiating vancomycin-resistant enterococci | OXOID LTD (GB) | 2012-07-25 | — | — | EP | claimed |
| EP-2186906-A2 | Medium for detecting and differentiating vancomycin-resistant enterococci | OXOID LIMITED (GB) | 2010-05-19 | — | — | EP | claimed |
| US-20100120086-A1 | MEDIUM FOR DETECTING AND DIFFERENTIATING VANCOMYCIN-RESISTANT ENTEROCOCCI | OXOID LTD. (GB) | 2010-05-13 | — | — | US | claimed |
| EP-4246147-B1 | METHOD FOR MEASURING STEROL IN LIPOPROTEIN, AND REAGENT FOR MEASURING STEROL IN LIPOPROTEIN | SYSMEX CORP (JP) | 2026-05-06 | — | — | EP | disclosed |
| EP-3855182-B1 | METHOD FOR OBTAINING INFORMATION ON COGNITIVE FUNCTION | SYSMEX CORP (JP) | 2026-04-29 | — | — | EP | disclosed |
| EP-3779457-B1 | METHOD AND REAGENT FOR MEASURING UPTAKE PERFORMANCE OF LIPOPROTEIN | SYSMEX CORP (JP) | 2026-04-29 | — | — | EP | disclosed |
| CN-121896315-A | Chromogenic medium for detecting staphylococcus aureus, preparation method thereof and test piece | 广州热泉科技有限公司 | 2026-04-21 | — | — | CN | disclosed |
| EP-4047017-B1 | MONOCLONAL ANTIBODY, MEASUREMENT REAGENT FOR CYTOKERATIN 18 FRAGMENT, REAGENT KIT, AND MEASUREMENT METHOD | SYSMEX CORP (JP) | 2026-03-04 | — | — | EP | disclosed |
| US-20260036584-A1 | COMPOSITIONS AND METHODS TO DETECT GASTROINTESTINAL DISEASE | THE BOARD OF SUPERVISORS OF LOUISIANA STATE UNIV AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2026-02-05 | — | — | US | disclosed |
| EP-3809135-B1 | METHOD AND REAGENT FOR MEASURING LIPOPROTEIN'S UPTAKE ABILITY | SYSMEX CORP (JP) | 2026-01-14 | — | — | EP | disclosed |
| EP-4623995-A1 | MONOCLONAL ANTIBODY, REAGENT FOR MEASURING CRTAC1B, REAGENT KIT, AND METHOD FOR MEASURING CRTAC1B | SYSMEX CORPORATION (JP) | 2025-10-01 | — | — | EP | disclosed |
| EP-2186906-A2 | Medium for detecting and differentiating vancomycin-resistant enterococci | OXOID LIMITED (GB) | 2010-05-19 | — | — | EP | disclosed |
| US-20100120086-A1 | MEDIUM FOR DETECTING AND DIFFERENTIATING VANCOMYCIN-RESISTANT ENTEROCOCCI | OXOID LTD. (GB) | 2010-05-13 | — | — | US | disclosed |
| EP-0874240-B1 | Enzyme-labeled immunoassay and device therefor | FUJIREBIO KK (JP) | 2002-07-31 | — | — | EP | disclosed |
| US-20010005585-A1 | Enzyme-labeled immunoassay and device therefor | FUJIREBIO INC. (JP) | 2001-06-28 | — | — | US | disclosed |
| US-6251618-B1 | REACTION OF INDOYL DERIVATIVE WITH ENZYME IN PRESENCE OF SPECIFIC FREE RADICAL COMPOUND AND/OR CHELATE COMPOUND REDUCES TIME REQUIRED FOR DEVELOPMENT | FUJIREBIO INC. (JP) | 2001-06-26 | — | — | US | disclosed |
| US-6221625-B1 | ALLOWING A TEST SAMPLE TO REACT WITH AN ENZYME-LABELED REAGENT, ALLOWING A SUBSTRATE TO REACT WITH THE ENZYME TO FORM A SIGNAL, AND IMMOBILISING THE ENZYME-LABELED REAGENT, WITH THE PREVENTION OF A FURTHER SIGNAL FORMATION | FUJIREBIO INC. (JP) | 2001-04-24 | — | — | US | disclosed |
| US-5998156-A | MEASURING ENZYME ACTIVITY USING ENZYME LABELED ANTIBODY OR ANTIGEN | FUJIREBIO INC. (JP) | 1999-12-07 | — | — | US | disclosed |
| EP-0874240-A1 | Enzyme-labeled immunoassay and device therefor | Fujirebio Inc. (JP) | 1998-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260036584-A1 | COMPOSITIONS AND METHODS TO DETECT GASTROINTESTINAL DISEASE | SI, FABP2, VIP | CSNK2A1 491/4885CYP1A2 3170/4885GSK3B 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.